A detailed history of Great West Life Assurance CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 7,525 shares of RVNC stock, worth $19,339. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,525
Previous 7,525 -0.0%
Holding current value
$19,339
Previous $19,000 105.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $49,321 - $107,801
4,300 Added 133.33%
7,525 $86,000
Q2 2023

Aug 10, 2023

SELL
$24.7 - $37.61 $23,983 - $36,519
-971 Reduced 23.14%
3,225 $82,000
Q4 2022

Feb 10, 2023

BUY
$18.32 - $30.66 $16,011 - $26,796
874 Added 26.31%
4,196 $78,000
Q2 2022

Aug 12, 2022

BUY
$11.52 - $20.4 $38,269 - $67,768
3,322 New
3,322 $46,000
Q2 2022

Aug 09, 2022

SELL
$11.52 - $20.4 $38,269 - $67,768
-3,322 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$24.03 - $29.97 $34,987 - $43,636
-1,456 Reduced 30.47%
3,322 $92,000
Q4 2020

Feb 16, 2021

BUY
$23.41 - $28.34 $47,475 - $57,473
2,028 Added 73.75%
4,778 $135,000
Q3 2020

Nov 17, 2020

SELL
$23.23 - $34.3 $5.1 Million - $7.53 Million
-219,494 Reduced 98.76%
2,750 $69,000
Q3 2020

Nov 13, 2020

BUY
$23.23 - $34.3 $5.1 Million - $7.53 Million
219,494 Added 7981.6%
222,244 $5.59 Million
Q4 2019

Feb 11, 2020

BUY
$11.66 - $20.15 $32,065 - $55,412
2,750 New
2,750 $44,000
Q3 2019

Oct 25, 2019

SELL
$10.22 - $14.5 $52,970 - $75,153
-5,183 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$15.4 - $20.39 $40,502 - $53,625
2,630 Added 103.02%
5,183 $81,000
Q3 2017

Nov 09, 2017

BUY
$22.55 - $28.1 $57,570 - $71,739
2,553
2,553 $69,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.